Rituximab: Applications in dermatology

被引：21
作者：
Fatourechi, Mitra M.
el-Azhary, Rokea A.
Gibson, Lawrence E.
机构：
[1] Mayo Clin & Mayo Fdn, Dept Dermatol, Rochester, MN 55905 USA
[2] Univ Minnesota, Sch Med, Off Student Affairs, Minneapolis, MN 55455 USA
来源：
INTERNATIONAL JOURNAL OF DERMATOLOGY | 2006年 / 45卷 / 10期
关键词：
D O I：
10.1111/j.1365-4632.2006.03007.x
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Rituximab is a chimeric anti-CD20 monoclonal antibody which has been used extensively for B-lymphocytic malignancies. In addition, applications for autoimmune diseases have emerged in recent years. Case reports support the use of rituximab in certain dermatologic conditions, including paraneoplastic pemphigus, pemphigus vulgaris, graft versus host disease, and cutaneous B-cell malignancies. Clinical trials are lacking and would be an appropriate next step.
引用
收藏
页码：1143 / 1155
页数：13
相关论文
共 96 条
[1]   Primary cutaneous large B-cell lymphoma of the legs - A distinct clinical pathologic entity treated with CD20 monoclonal antibody (Rituximab) [J].
Aboulafia, DM .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (03) :237-240
[2]   A 79-year-old woman with gastric lymphoma and erosive mucosal and cutaneous lesions - Paraneoplastic pemphigus associated with gastric marginal-zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) [J].
Ahmed, AR ;
Kelly, JL ;
Avram, MM ;
McCluskey, RT ;
Ryan, DP ;
Duncan, LM .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (04) :382-391
[3]   Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma [J].
Aklilu, M ;
Stadler, WM ;
Markiewicz, M ;
Vogelzang, NJ ;
Mahowald, M ;
Johnson, M ;
Gajewski, TF .
ANNALS OF ONCOLOGY, 2004, 15 (07) :1109-1114
[4]   Paraneoplastic pemphigus [J].
Anhalt, GJ .
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, 2004, 9 (01) :29-33
[5]   PARANEOPLASTIC PEMPHIGUS - AN AUTOIMMUNE MUCOCUTANEOUS DISEASE ASSOCIATED WITH NEOPLASIA [J].
ANHALT, GJ ;
KIM, S ;
STANLEY, JR ;
KORMAN, NJ ;
JABS, DA ;
KORY, M ;
IZUMI, H ;
RATRIE, H ;
MUTASIM, D ;
ARISSABDO, L ;
LABIB, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (25) :1729-1735
[6]   Cutaneous graft-versus-host disease [J].
Aractingi, S ;
Chosidow, O .
ARCHIVES OF DERMATOLOGY, 1998, 134 (05) :602-612
[7]   Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab) [J].
Arzoo, K ;
Sadeghi, S ;
Liebman, HA .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (10) :922-924
[8]   INCIDENCE AND SIGNIFICANCE OF ORGAN-SPECIFIC AUTOIMMUNE DISORDERS (CLINICAL, LATENT OR ONLY AUTOANTIBODIES) IN PATIENTS WITH VITILIGO [J].
BETTERLE, C ;
CARETTO, A ;
DEZIO, A ;
PEDINI, B ;
VELLERFORNASA, C ;
CECCHETTO, A ;
ACCORDI, F ;
PESERICO, A .
DERMATOLOGICA, 1985, 171 (06) :419-423
[9]   Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab [J].
Bonnekoh, B ;
Schulz, M ;
Franke, I ;
Gollnick, H .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2002, 128 (03) :161-166
[10]  
Borradori L, 2001, ARCH DERMATOL, V137, P269
12345678910